rafal_olechowski Xeris Biopharma (NASDAQ:XERS) traded ~11% higher premarket Wednesday after signing an exclusive licensing deal for Amgen (NASDAQ:AMGN) to launch a subcutaneous version of the latter’s thyroid eye disease therapy, Tepezza. Per the terms, Xeris (XERS) will join Amgen (AMGN) to develop, manufacture, and commercialize a subcutaneous version of Tepezza globally using its XeriJect technology.

rafal\u olechowski Xeris Biopharma（纳斯达克股票代码：XERS）周三在上市前上涨了约11%，此前该公司与安进（纳斯达克股票代码：AMGN）签署了独家许可协议，推出了后者的甲状腺眼病疗法Tepezza的皮下版本。根据条款，Xeris（XERS）将加入Amgen（AMGN），使用其XeriJect技术在全球范围内开发，制造和商业化皮下版本的Tepezza。

The agreement can lead to $75M in development and regulatory milestones for Xeris (XERS) in addition to sales-based milestone payments. The company will also be eligible for single-digit royalties linked to future Tepezza sales based on XeriJect technology. “We will move quickly to support our partner in this important development program,” Xeris (XERS) CEO Paul Edick remarked.

除了基于销售的里程碑付款外，该协议还可以为Xeris（XERS）带来7500万美元的开发和监管里程碑。该公司还将有资格获得与基于XeriJect技术的未来Tepezza销售相关的单位数字版税。“我们将迅速采取行动，在这一重要的发展计划中支持我们的合作伙伴，”Xeris（XERS）首席执行官保罗·艾迪克表示。

Also known as teprotumumab-trbw, Tepezza became part of Amgen’s (AMGN) portfolio following the company's ~$28B acquisition of rare disease drugmaker Horizon Therapeutics in October. More on Amgen Amgen Inc. (AMGN) Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024 (Transcript) Amgen: Wonderful Stock At Decent Price Amgen: Bet On Its Breakthrough Drug Pharma and biotech deal values spike 35% in 2023: report Amgen says FDA declined full approval for lung cancer drug Lumakras .

Tepezza也被称为teprotumumab trbw，在该公司10月以约280亿美元收购罕见病制药商Horizon Therapeutics之后，它成为安进（AMGN）投资组合的一部分。关于安进安进公司（AMGN）的更多信息，请参阅摩根大通第42届2024年年度医疗保健会议（成绩单）安进安进：股价不错的股票安进安进：押注其突破性的药物制药和生物技术交易价值在2023年飙升35%：安进安进报告称FDA拒绝完全批准肺癌药物Lumakras。